Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2018025459
pages 59-91

Pancreatic Cancer: Recent Advances in Nanoformulation-Based Therapies

Preshita Desai
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA
David Ann
Department of Diabetes Complications and Metabolism, City of Hope, Duarte, California, USA
Jeffrey Wang
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA
Sunil Prabhu
Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA

ABSTRACT

Pancreatic cancer is the fourth leading cause of death in the United States and has a 5-year life expectancy of ~8%. Currently, only a few drugs have been approved by the United States Food and Drug Administration for pancreatic cancer treatment. Despite available drug therapy and ongoing clinical investigations, the high prevalence and mortality associated with pancreatic cancer mean that there is an unmet chemopreventive and therapeutic need. From ongoing studies with various novel formulations, it is evident that the development of smart drug delivery systems will improve delivery of drug cargo to the pancreatic target site to ensure and enhance the therapeutic/chemoprevention efficacy of existing drugs and newly designed drugs in the future. With this in view, nanotechnology is emerging as a promising avenue to enhance drug delivery to the pancreas via both passive and active targeting mechanisms. Research in this field has grown extensively over the past decade, as is evident from available scientific literature. This review summarizes the recent advances that have brought nanotechnology-based formulations to the forefront of pancreatic cancer treatment.


Articles with similar content:

A Review of the Application of Lipid-Based Systems in Systemic, Dermal/ Transdermal, and Ocular Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 6
Kishor M. Wasan, Pavel Gershkovich, Cheri A. Barta
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria
Microsponges: A Pioneering Tool for Biomedical Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 1
Amit Verma, Ankit Jain, Pooja Hurkat, Amrita Kumari, Sanjay Kumar Jain
Bioconjugates: Harnessing Potential for Effective Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 2
Vandana Soni, Piush Khare, Nitin K. Jain, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain
Conundrum and Therapeutic Potential of Curcumin in Drug Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 4
Javed Ali, Sanjula Baboota, Anil Kumar, Alka Ahuja